Cedric O’Gorman

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia

Christoph U. Correll, Robert E. Davis, Michal Weingart et al. · JAMA Psychiatry · 2020 · 279 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity

Martin Strassnig, Tenko Raykov, Cedric O’Gorman et al. · Schizophrenia Research · 2015 · 175 citations · Full text

Medicine, Psychiatry, Psychology +17

Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients

Christoph U. Correll, Benjamin G. Druss, Ilise Lombardo et al. · Psychiatric Services · 2010 · 113 citations

Medicine, Psychiatry, Public Health Practice +16

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder

Jeffrey Miceli, Thomas G. Tensfeldt, Thomas Shiovitz et al. · Clinical Therapeutics · 2010 · 45 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder

Jeffrey Miceli, Thomas G. Tensfeldt, Thomas Shiovitz et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2010 · 42 citations

Medicine, Pharmacology, Psychiatry +15